Page last updated: 2024-11-05

anthrarufin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,5-dihydroxyanthraquinone: used in ferric ion sensing as an inclusion complex with beta-cyclodextrin; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anthrarufin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8328
CHEMBL ID55761
CHEBI ID37501
SCHEMBL ID187843
MeSH IDM0550554

Synonyms (55)

Synonym
1,5-dihydroxy-9,10-anthraquinone
nsc 7211
nsc 646570
1,5-dihydroxyanthrachinon [czech]
einecs 204-175-6
brn 1881718
ccris 3150
anthrarufin
1,5-dihydroxyanthrachinon
1,5-dihydroxyanthraquinone
nsc7211
9, 1,5-dihydroxy-
117-12-4
nsc-7211
wln: l c666 bv ivj dq kq
anthraquinone,5-dihydroxy-
NCI60_041483
nsc-646570
CHEBI:37501 ,
az-u
9,10-anthracenedione, 1,5-dihydroxy-
anthraquinone, 1,5-dihydroxy-
nsc646570
1,5-dihydroxy-9,10-anthracenedione
1,5-dihydroxyanthracene-9,10-dione
inchi=1/c14h8o4/c15-9-5-1-3-7-11(9)14(18)8-4-2-6-10(16)12(8)13(7)17/h1-6,15-16
anthrarufin, technical grade, 85%
D0562
AKOS001583186
1,5-dihydroxy-anthraquinone
CHEMBL55761
STK803592
A803716
kpb60w5s3m ,
4-08-00-03268 (beilstein handbook reference)
unii-kpb60w5s3m
BBL013162
FT-0622425
EPITOPE ID:116190
anthrarufin [mi]
SCHEMBL187843
DTXSID8051594
1,5-dihydroxyanthra-9,10-quinone #
W-108570
mfcd00001210
1,5-dihydroxy-9,10-dihydroanthracene-9,10-dione
5,9-dihydroxy-1,10-anthraquinone
9,10-dihydroxy-1,5-anthraquinone
1,5-dihydroxyanthra-9,10-quinone
Q27117170
1,5-dihydroxyanthraquinone, tech.
AS-15880
bdbm50568423
SY017889
F71867
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dihydroxyanthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TransthyretinHomo sapiens (human)IC50 (µMol)100.00000.16004.292110.0000AID1755162
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)30.80000.00002.37899.7700AID1888748
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID336956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID102411Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 3 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1888752Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate at 100 uM after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID336953Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID336960Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio
AID336958Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio
AID398698Inhibition of lipid peroxidation in Sprague-Dawley rat heart mitochondria assessed as inhibition of FeSO4-induced oxygen consumption up to 0.3 mM relative to control1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID336957Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio
AID398699Inhibition of lipid peroxidation in Sprague-Dawley rat heart mitochondria assessed as inhibition of FeSO4-induced malondialdehyde formation up to 0.3 mM relative to control1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID336955Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID336954Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1877819Antiproliferative activity against human A-431 cells overexpressing EGFR assessed as reduction in cell survival at 10 uM2022Bioorganic & medicinal chemistry letters, 02-15, Volume: 58Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation.
AID336959Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio
AID1755162Inhibition of acid-mediated aggregation of TTR V30M mutant (unknown origin) expressed in Escherichia coli pretreated for 30 mins at pH 7 followed by protein dilution in acetate buffer and further incubated for 96 hrs at pH 4.6 by thioflavin-T fluorescence2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID102410Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 10 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID102409Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 1 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1888748Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's1 (14.29)24.3611
2020's3 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.85 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index65.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]